#### Coronary protection during TAVR: When and how?

Lars Sondergaard, MD, DMSc, FESC Professor of Cardiology The Heart Center, Rigshospitalet Copenhagen University Hospital, Denmark

AP VALVES & ETHIL STRUCTURAL HEART

#### In selected patients:


# Coronary artery occlusion during TAVR is a rare but often fatal complication!

#### Patients at risk:


- Native aortic valve stenosis
- VinV for degenerated bioprosthetic aortic valve

#### Native aortic valve

High coronary take-off Wide sinus of Valsalva High sinotubular junction Short non-calcified cusps




Low coronary take-off Shallow sinus of Valsalva Low sinotubular junction Long calcified cusps




Mercanti et al. J Am Coll Cardiol Intv 2020;13:751-61

## TAVR in degenerated surgical bioprostheses

High coronary take-off Wide sinus of Valsalva High sinotubular junction




Low coronary take-off Shallow sinus of Valsalva Low sinotubular junction



Mercanti et al. J Am Coll Cardiol Intv 2020;13:751-61


#### TAVR in degenerated surgical bioprostheses



#### Valve-to-Coronary (VTC):

#### <4 mm a risk factor!

#### Know your transcatheter heart valve!



## Surgical bioprosthetic valve types

#### Stented bioprosthesis



#### Stentless bioprosthesis



**Freedom Solo** 

Mosaic Mitroflow & Trifecta Leaflets sutured 'outside' stent

## High risk of coronary occlusion

#### Stented bioprosthesis



Mosaic


Mitroflow & Trifecta Leaflets sutured 'outside' stent

#### Stentless bioprosthesis




Freedom Solo

#### Coronary occlusion in VinV



Ribeiro et al. EHJ 2018; 39:687-95


#### Coronary access after TAVR-in-TAVR



Low-frame Intra-annular leaflets High-frame Intra-annular leaflets High-frame supra-annular leaflets

Sondergaard. EuroIntervention. 2018; 14:147-9

## Coronary flow assessment during BAV




- Balloon with same diameter as true ID
- Simultaneously aortic root injection
- Confirm that coronary flow is unaffected

#### TAVR with surgical team stand-by



- Surgeon in the room
- Heart-lung machine primed
- Introducer sheath -> arterial cannula
- Venous access, stiff-guide wire in IVC

#### Chimney stenting



Patient at risk. Safety wire and stent Valve deployment with safety wire and stent Chimney stenting if coronary obstruction Simultaneous kissing (only if postdilatation of TAVR required) Final result

## Frequency of chimney stenting

#### 60 (0.5%) procedures in 12,800 TAVR

- 18 native aortic annulus
- 42 VinV

Mercanti et al. J Am Coll Cardiol Intv 2020;13:751-61

#### 30-day clinical outcomes

|                                |                   | CAO              |                  |         |
|--------------------------------|-------------------|------------------|------------------|---------|
|                                | Total<br>(N = 60) | iCAO<br>(n = 35) | eCAO<br>(n = 25) | p Value |
| Procedural death               | 3 (5.0)           | 0 (0.0)          | 3 (12.0)         | 0.07    |
| 30-day death                   | 3 (5.0)           | 0 (0.0)          | 3 (12.0)         | 0.07    |
| MI                             | 13 (21.6)         | 0 (0.0)          | 13 (52.0)        | <0.01   |
| Cardiogenic shock              | 14 (23.3)         | 1 (2.9)          | 13 (52.0)        | <0.01   |
| Stroke                         | 1 (1.7)           | 0 (0.0)          | 1 (4.0)          | _       |
| Major vascular<br>complication | 2 (3.4)           | 1 (2.9)          | 1 (4.0)          | 0.7     |
| Life-threatening<br>bleeding   | 1 (1.7)           | 0 (0.0)          | 1 (4.0)          | -       |
| AKI grade 3                    | 3 (5.0)           | 1 (2.9)          | 2 (8.0)          | 0.4     |

Mercanti et al. J Am Coll Cardiol Intv 2020;13:751-61

| TABLE 6 Predictors of 30-Day Death, Myocardial Infarction, and Cardiogenic Shock |                     |            |         |                       |            |         |  |
|--|---------------------|------------|---------|-----------------------|------------|---------|--|
|  | Univariate Analysis |            |         | Multivariate Analysis |            |         |  |
|  | Odds<br>Ratio       | 95% CI     | p Value | Odds<br>Ratio         | 95% CI     | p Value |  |
| Absence of coronary protection   | 8.81                | 2.41-32.16 | <0.01   | 7.39                  | 1.95-27.93 | <0.01   |  |
| No VIV   | 1.41                | 0.43-4.67  | 0.6     |                       |            |         |  |
| Balloon-expandable THV   | 3.36                | 1.01-11.18 | 0.05    | 2.18                  | 0.56-8.43  | 0.26    |  |
| SOV diameter <30 mm  | 1.93                | 0.60-6.23  | 0.27    |                       |            |         |  |
| Coronary height <10 mm   | 2.16                | 0.41-11.37 | 0.36    |                       |            |         |  |
| VTC ≤4 mm*   | 1.54                | 0.34-6.93  | 0.58    |                       |            |         |  |

Mercanti et al. J Am Coll Cardiol Intv 2020;13:751–61

## Stent failure after chimney stenting (3.5%)

#### Median follow-up 612 days (IQR 405-842 days)


- 1 in-stent restenosis (day 157)
- 1 possible late stent thrombosis (day 374)


#### **BASILICA** - laceration of cusp


Leaflet wire transversal and snaring

Leaflet slicing

Preserved coronary flow







## Anatomically considerations for BASILICA

| Favorable for BASILICA   | Unfavorable for BASILICA   |
|--|--|
| Typical calcium pattern which spares the nadir of the leaflet  | Confluent calcium at the leaflet nadir                                       |
|  | Bulky calcium mass on the leaflet  |
| Commissures aligned with native commissures                    | Bioprosthetic valve post in-front of coronary artery ostium                  |
| Femoral access for BASILICA catheters preferred for ergonomics | Nonfemoral access (femoral artery or transcaval) for double leaflet BASILICA |
| Single leaflet BASILICA  | Double BASILICA not recommended for new operators in                         |
| Risk from sinus sequestration                                  | their first 2–3 cases  |

## **Clinical outcomes with BASILICA**

Native aortic valve: 13 (43%), surgical bioprosthesis 17 (57%)

| Clinical outcomes           | At 30 days (n=30) | At 1 y (n=30) |
|-----------------------------|-------------------|---------------|
| All death                   | 1 (3.3%)          | 3 (10%)       |
| Cardiovascular              | 1 (3.3%)          | 2 (6.7%)      |
| Noncardiovascular           | 0 (0%)            | 1 (3.3%)      |
| All stroke                  | 3 (10%)           | 3 (10%)       |
| Disabling                   | 1 (3.3%)          | 1 (3.3%)      |
| Nondisabling                | 2 (6.7%)          | 2 (6.7%)      |
| Coronary artery obstruction | 0 (0%)            | 0 (0%)        |

Khan et al. Circ Interv 2021

## Summary

- Coronary occlusion is rare in native aortic annuli, but a risk during VinV procedures
- Pre-procedural CT may identify patients at risk
- Chimney stenting relative simple and safe, but concerns regarding re-access and stent failure
- BASILICA more technical challenging and may fail

## Coronary occlusion during TAVR: If you think about it, protect it!